9/20/2013 10:06:32 AM
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced the launch of the generic equivalent to NIASPAN® (niacin extended-release) tablets, 500, 700, and 1000mg in the United States. Teva was first to file, making the product eligible for 180 days of marketing exclusivity.
Help employers find you! Check out all the jobs and post your resume.
comments powered by